Pharmaceutical

J&J asserts its place in atopic dermatitis space with Yellow Jersey acquisition

J&J gains Phase II ready NM26, a bispecific antibody in development for the treatment of atopic dermatitis.

Jul 12, 2024 - 04:00
J&J asserts its place in atopic dermatitis space with Yellow Jersey acquisition
J&J gains Phase II ready NM26, a bispecific antibody in development for the treatment of atopic dermatitis.
Read the original article

Tags:

Previous Article

BARDA and Tiba Biotech link to develop ‘flu therapeutics

Next Article

Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

StromaForte by Swedish StromaBio for Cardiovascular Dis...

Nov 6, 2023

Syros Pharmaceuticals gets grant for CDK7 inhibitors for treating cancer and other diseases

Syros Pharmaceuticals gets grant for CDK7 inhibitors fo...

Jun 12, 2024

Novo Nordisk to invest $2.3bn to expand Danish manufacturing facilities

Novo Nordisk to invest $2.3bn to expand Danish manufact...

Jun 13, 2023